PHARMING GROUP NV (PHARM.AS)

NL0010391025 - Common Stock

0.893  +0.02 (+2.23%)

Fundamental Rating

3

Overall PHARM gets a fundamental rating of 3 out of 10. We evaluated PHARM against 74 industry peers in the Biotechnology industry. PHARM scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PHARM is valied quite expensively at the moment, while it does show a decent growth rate.



3

1. Profitability

1.1 Basic Checks

PHARM had negative earnings in the past year.
In the past year PHARM had a positive cash flow from operations.
Of the past 5 years PHARM 4 years were profitable.
Of the past 5 years PHARM 4 years had a positive operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -4.19%, PHARM is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
PHARM's Return On Equity of -7.89% is fine compared to the rest of the industry. PHARM outperforms 66.67% of its industry peers.
Industry RankSector Rank
ROA -4.19%
ROE -7.89%
ROIC N/A
ROA(3y)1.65%
ROA(5y)5.8%
ROE(3y)3.38%
ROE(5y)12.69%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

PHARM has a better Gross Margin (89.39%) than 86.96% of its industry peers.
In the last couple of years the Gross Margin of PHARM has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for PHARM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 89.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.31%
GM growth 5Y1.43%

4

2. Health

2.1 Basic Checks

PHARM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PHARM has more shares outstanding
The number of shares outstanding for PHARM has been increased compared to 5 years ago.
Compared to 1 year ago, PHARM has an improved debt to assets ratio.

2.2 Solvency

PHARM has an Altman-Z score of 0.44. This is a bad value and indicates that PHARM is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 0.44, PHARM perfoms like the industry average, outperforming 52.17% of the companies in the same industry.
PHARM has a Debt/Equity ratio of 0.53. This is a neutral value indicating PHARM is somewhat dependend on debt financing.
PHARM's Debt to Equity ratio of 0.53 is in line compared to the rest of the industry. PHARM outperforms 42.03% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.53
Debt/FCF N/A
Altman-Z 0.44
ROIC/WACCN/A
WACC5.15%

2.3 Liquidity

A Current Ratio of 3.53 indicates that PHARM has no problem at all paying its short term obligations.
With a decent Current ratio value of 3.53, PHARM is doing good in the industry, outperforming 66.67% of the companies in the same industry.
PHARM has a Quick Ratio of 2.76. This indicates that PHARM is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 2.76, PHARM is doing good in the industry, outperforming 60.87% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.53
Quick Ratio 2.76

5

3. Growth

3.1 Past

PHARM shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.13%.
PHARM shows a strong growth in Revenue. In the last year, the Revenue has grown by 30.64%.
Measured over the past years, PHARM shows a quite strong growth in Revenue. The Revenue has been growing by 11.35% on average per year.
EPS 1Y (TTM)-3.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-140%
Revenue 1Y (TTM)30.64%
Revenue growth 3Y4.96%
Revenue growth 5Y11.35%
Sales Q2Q%12.28%

3.2 Future

PHARM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 57.08% yearly.
The Revenue is expected to grow by 9.73% on average over the next years. This is quite good.
EPS Next Y31.31%
EPS Next 2Y17.15%
EPS Next 3Y48.69%
EPS Next 5Y57.08%
Revenue Next Year19.58%
Revenue Next 2Y15.29%
Revenue Next 3Y14.42%
Revenue Next 5Y9.73%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PHARM. In the last year negative earnings were reported.
Also next year PHARM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -55.58

4.3 Compensation for Growth

A more expensive valuation may be justified as PHARM's earnings are expected to grow with 48.69% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.15%
EPS Next 3Y48.69%

0

5. Dividend

5.1 Amount

PHARM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

PHARMING GROUP NV

AMS:PHARM (12/24/2024, 7:00:00 PM)

0.893

+0.02 (+2.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-24 2024-10-24/bmo
Earnings (Next)N/A N/A
Inst Owners16.21%
Inst Owner ChangeN/A
Ins Owners1.48%
Ins Owner ChangeN/A
Market Cap60.58M
Analysts86.67
Price Target7.06 (690.59%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-87.38%
Min EPS beat(2)-197.09%
Max EPS beat(2)22.33%
EPS beat(4)1
Avg EPS beat(4)-169.28%
Min EPS beat(4)-363.52%
Max EPS beat(4)22.33%
EPS beat(8)3
Avg EPS beat(8)-130.32%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-4.45%
Min Revenue beat(2)-5.54%
Max Revenue beat(2)-3.36%
Revenue beat(4)1
Avg Revenue beat(4)-5.41%
Min Revenue beat(4)-21.13%
Max Revenue beat(4)8.39%
Revenue beat(8)3
Avg Revenue beat(8)-5.11%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.48%
PT rev (3m)-2.48%
EPS NQ rev (1m)0%
EPS NQ rev (3m)125%
EPS NY rev (1m)0%
EPS NY rev (3m)-77.83%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.98%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.06%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.22
P/FCF N/A
P/OCF 139.62
P/B 0.28
P/tB 0.4
EV/EBITDA -55.58
EPS(TTM)-0.03
EYN/A
EPS(NY)-0.01
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.01
OCFY0.72%
SpS4.05
BVpS3.2
TBVpS2.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.19%
ROE -7.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 89.39%
FCFM N/A
ROA(3y)1.65%
ROA(5y)5.8%
ROE(3y)3.38%
ROE(5y)12.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.31%
GM growth 5Y1.43%
F-Score6
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 0.53
Debt/FCF N/A
Debt/EBITDA 71.79
Cap/Depr 6.22%
Cap/Sales 0.35%
Interest Coverage N/A
Cash Conversion 27.01%
Profit Quality N/A
Current Ratio 3.53
Quick Ratio 2.76
Altman-Z 0.44
F-Score6
WACC5.15%
ROIC/WACCN/A
Cap/Depr(3y)36.48%
Cap/Depr(5y)146.44%
Cap/Sales(3y)3.32%
Cap/Sales(5y)6.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-140%
EPS Next Y31.31%
EPS Next 2Y17.15%
EPS Next 3Y48.69%
EPS Next 5Y57.08%
Revenue 1Y (TTM)30.64%
Revenue growth 3Y4.96%
Revenue growth 5Y11.35%
Sales Q2Q%12.28%
Revenue Next Year19.58%
Revenue Next 2Y15.29%
Revenue Next 3Y14.42%
Revenue Next 5Y9.73%
EBIT growth 1Y62.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year82.14%
EBIT Next 3Y94.6%
EBIT Next 5Y62.69%
FCF growth 1Y-102.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-98.64%
OCF growth 3YN/A
OCF growth 5YN/A